People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
The FDA announced it has approved the abbreviated new drug application for pioglitazone, indicated for the treatment of type 2 diabetes in addition to diet and exercise.
Doctors at the university will begin studies in human beings later this year. Hopes are high, even though many drugs that work in mice do not work in humans.
Researchers at the University of Michigan’s Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.
Pain researcher Rebecca Sudore, MD, says, “Adults living with Type 2 diabetes are suffering from incredibly high rates of pain, at levels similar to patients living with cancer.” Sounds awful. But what can we do about it? Actually, quite a bit.
All three drugs contain a new active ingredient, alogliptin, either alone or in combination with other, previously approved medications. The newly approved drugs include Nesina (alogliptin), Kazano (alogliptin plus metformin) and Oseni (alogliptin plus pioglitazone).
In a trial of 12 patients with Type 1 diabetes, Biodel’s two formulations showed significantly more rapid absorption rates and declines from peak concentrations. Discomfort levels associated with BIOD-250 were comparable to Humalog, though those related to BIOD-238 were significantly higher.
Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Monday it got the final go-ahead from authorities to market its long-acting diabetes drug Tresiba in Europe.
A Chinese research study of diabetes patients with coronary heart disease concludes that metformin is more effective than glipizide in reducing the risk of major cardiovascular events, such as stroke and heart attack.
New research has found that people who have had diabetes for a long time are more likely to be diagnosed with cancer than those who have had it for a shorter time.
GI Dynamics, Inc. (ASX: GID) have announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier®, the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
Israel-based Oramed announced that it has sent an application to the Food and Drug Administration for permission to enter Phase 2 trials of its oral insulin product.
A group of researchers from the university’s School of Science, led by Dr Solomon Habtemariam, believe they have identified potential sources of medicines derived from plants which may have fewer adverse side-effects for diabetes sufferers.
GlaxoSmithKline has announced a regulatory submission to the U.S. Food and Drug Administration for its type 2 diabetes drug called albigultide.
A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.
Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.
Federal drug reviewers think Johnson & Johnson’s experimental diabetes drug might bring heart risks because it raised cholesterol levels in patient testing.
Eli Lilly and Co and Boehringer Ingelheim said on Monday that an experimental treatment for type 2 diabetes, empagliflozin, met the primary goal of significantly lowering blood sugar levels in four late-stage trials.
Research in mice found that metformin suppresses the liver hormone glucagon’s ability to generate an important signaling molecule, pointing to new drug targets. The findings were published online this week in Nature.
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker’s eye treatment, recommending the pricey injection for use in diabetics.